About 2 results found for searched term "Ralimetinib" (0.097 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2318 | LY2228820 | p38 MAPK |
| Ralimetinib dimesylate; LY2228820 dimesylate; LY2228820 2MsOH | ||
| LY2228820 is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM. | ||
| M30721 | Ralimetinib | p38 MAPK |
| LY2228820 | ||
| Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
